aTyr Pharma, Inc.

Equities

LIFE

US0021202025

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
1.95 ^USD	-5.80%		+7.14%	+38.30%

May. 14	ATyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT? Study in Pulmonary Sarcoidosis	CI
May. 02	ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

ATyr Pharma, Inc. Announces Executive Changes

December 11, 2017 at 05:00 pm EST

aTyr Pharma, Inc. announced that Sanuj K. Ravindran, M.D., the company's Chief Business Officer, agreed upon a transition plan whereby Dr. Ravindran will transition from his role as Chief Business Officer to that of a business advisor to the company. Dr. Ravindran's last day of employment with the company will be December 31, 2017.

Latest news about aTyr Pharma, Inc.

ATyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT? Study in Pulmonary Sarcoidosis	May. 14	CI
ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000	May. 02	MT
RBC Cuts Price Target on aTyr Pharma to $16 From $19, Keeps Outperform Rating, Speculative Risk Qualifier	Mar. 15	MT
Transcript : ATyr Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024	Mar. 14
ATyr Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
ATyr Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
ATyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis	Feb. 21	CI
ATyr Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Earnings Flash (LIFE) ATYR PHARMA Posts Q3 Revenue $353,000	Nov. 09	MT
Atyr Pharma, Inc. Announces Dosing of First Patient in Phase 2 Efzo-Connect?? Study of Efzofitimod in Patients with Ssc-Ild	23-10-31	CI
Top Premarket Gainers	23-10-04	MT
Atyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, Fvc and Patient Reported Outcomes	23-09-11	CI
ATyr Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Piper Sandler Adjusts Price Target on aTyr Pharma to $20 From $13, Maintains Overweight Rating	23-07-21	MT
North American Morning Briefing : Fed Hawks Hit -2-	23-07-06	DJ
Oppenheimer Downgrades aTyr Pharma to Perform From Outperform, Removes $17 Price Target	23-07-05	MT
ATyr Pharma, Inc.(NasdaqCM:LIFE) added to Russell 3000E Growth Index	23-06-23	CI
ATyr Pharma, Inc.(NasdaqCM:LIFE) added to Russell Microcap Growth Index	23-06-23	CI
ATyr Pharma's Efzofitimod Gets Orphan Drug Label from European Commission for Systemic Sclerosis	23-06-22	MT
Insider Buy: aTYR Pharma	23-05-11	MT
ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Piper Sandler Adjusts Price Target on aTyr Pharma to $13 From $9, Keeps Overweight Rating	23-04-11	MT
Certain Common Stock of aTyr Pharma, Inc. are subject to a Lock-Up Agreement Ending on 10-APR-2023.	23-04-09	CI
Certain Warrants of aTyr Pharma, Inc. are subject to a Lock-Up Agreement Ending on 10-APR-2023.	23-04-09	CI

Chart aTyr Pharma, Inc.

Duration

Period

More charts

Company Profile

aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).

Sector

Biotechnology & Medical Research

Calendar

2024-05-21 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for aTyr Pharma, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.95 USD

Average target price

22.6 USD

Spread / Average Target

+1,058.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ATYR PHARMA, INC.	+38.30%	143M
MODERNA, INC.	+44.48%	54.04B
LONZA GROUP AG	+43.57%	41.96B
IQVIA HOLDINGS INC.	-0.86%	41.92B
CELLTRION, INC.	-7.59%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.30%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.83%	19B
BIO-TECHNE CORPORATION	+7.15%	13B
MEDPACE HOLDINGS, INC.	+29.40%	12.28B
UNITED THERAPEUTICS CORPORATION	+25.15%	12.19B

Other Biotechnology & Medical Research